doi:10.1038/s43016-025-01282-0 Jovanovski E, Mazhar N, Komishon A, et al
Meng X, Song J, Lei Y, et al
Incretin-based therapies: review of current clinical trial data
As a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, it works by mimicking naturally occurring hormones that regulate blood sugar levels and appetite
The pathway for compounded GLP-1s has not closed entirely: legitimate patient-specific 503A compounding, with individualized clinical documentation, at the four-prescription safe harbor ceiling, remains legally available for genuine edge cases such as documented allergies to branded product excipients
Shipping Retatrutide without proper insulation, relying on standard courier services without cold chain protection, or failing to track temperature during transit are all risky practices